Outcome of transcatheter atrial septal defect closure in a nationwide cohort

AbstractBackground Transcatheter (TC) atrial septal defect (ASD) closure has been the mainstay of therapy for secundum-type ASDs for over 20 years.Aims This nationwide cohort evaluated the long-term outcome of transcatheter-closed ASDs.Methods The study enrolled every transcatheter ASD closure perfo...

Full description

Bibliographic Details
Main Authors: V. Muroke, M. Jalanko, J. Haukka, J. Hartikainen, A. Tahvanainen, H. Ukkonen, K. Ylitalo, J. Pihkala, J. Sinisalo
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Annals of Medicine
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2023.2178669
_version_ 1797353764954308608
author V. Muroke
M. Jalanko
J. Haukka
J. Hartikainen
A. Tahvanainen
H. Ukkonen
K. Ylitalo
J. Pihkala
J. Sinisalo
author_facet V. Muroke
M. Jalanko
J. Haukka
J. Hartikainen
A. Tahvanainen
H. Ukkonen
K. Ylitalo
J. Pihkala
J. Sinisalo
author_sort V. Muroke
collection DOAJ
description AbstractBackground Transcatheter (TC) atrial septal defect (ASD) closure has been the mainstay of therapy for secundum-type ASDs for over 20 years.Aims This nationwide cohort evaluated the long-term outcome of transcatheter-closed ASDs.Methods The study enrolled every transcatheter ASD closure performed in Finland from 1999 to 2019. Five age, sex, and municipality-matched controls per ASD patient were gathered from the general population. The median follow-up period was 5.9 years (range 0–20.8). We used the hospital discharge register to gather all hospital visits and diagnoses. Closure complications and echocardiographic changes were collected from the electronic health records.Results Transcatheter ASD closure was performed in 1000 patients (68.5% females) during the study period. The median (range) age at the time of the procedure was 37.9 (1.8–87.5) years. ASD patients had an increased risk for new-onset atrial fibrillation (RR 2.45, 95% CI: 1.84–3.25), migraine (RR 3.61, 95% CI: 2.54–5.14), ischemic heart disease (RR 1.73, 95% CI: 1.23–2.45), ventricular fibrillation/tachycardia (RR 3.54 (95% CI: 1.48–8.43) and AV conduction disorder (RR 3.60, 95% CI: 1.94–6.70) compared to the control cohort. Stroke risk was not increased (RR 1.36, 95% CI: 0.91–2.03). Adverse events occurred in 6.3% (n = 63) of the patients, including four erosions and ten device embolizations.Conclusion After TC closure of ASD, patients had a higher risk of new-onset atrial fibrillation and migraine than controls without ASD. As novel findings, we found an increased risk for ischemic heart disease, AV conduction disorders, and ventricular fibrillation/tachycardia.Key messagesEven though patients have an excellent overall prognosis after percutaneous ASD closure, the increased incidence of major comorbidities like atrial fibrillation and heart failure prompts more thorough lifelong follow-up.This study’s novel findings revealed the increased risk for ischemic heart disease, AV conduction disorders, or ventricular tachycardia/fibrillation during the follow-up.Major complications after the closure are rare; erosion is seen in 0.4% of the patients and embolization in 1.0% of the patients.
first_indexed 2024-03-08T13:35:44Z
format Article
id doaj.art-c78f439f344146dcb3d96950828eda1d
institution Directory Open Access Journal
issn 0785-3890
1365-2060
language English
last_indexed 2024-03-08T13:35:44Z
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series Annals of Medicine
spelling doaj.art-c78f439f344146dcb3d96950828eda1d2024-01-16T19:13:20ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602023-12-0155161562310.1080/07853890.2023.2178669Outcome of transcatheter atrial septal defect closure in a nationwide cohortV. Muroke0M. Jalanko1J. Haukka2J. Hartikainen3A. Tahvanainen4H. Ukkonen5K. Ylitalo6J. Pihkala7J. Sinisalo8Department of Cardiology, Helsinki University Hospital, Helsinki, FinlandDepartment of Cardiology, Helsinki University Hospital, Helsinki, FinlandDepartment of Public Health, University of Helsinki, Helsinki, FinlandDepartment of Cardiology, Kuopio University Hospital, Kuopio, FinlandDepartment of Cardiology, Tampere University Hospital, Tampere, FinlandHeart Centre, Turku University Hospital, Turku, FinlandDepartment of Cardiology, Oulu University Hospital, Oulu, FinlandDepartment of Cardiology, New Children’s Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, FinlandDepartment of Cardiology, Helsinki University Hospital, Helsinki, FinlandAbstractBackground Transcatheter (TC) atrial septal defect (ASD) closure has been the mainstay of therapy for secundum-type ASDs for over 20 years.Aims This nationwide cohort evaluated the long-term outcome of transcatheter-closed ASDs.Methods The study enrolled every transcatheter ASD closure performed in Finland from 1999 to 2019. Five age, sex, and municipality-matched controls per ASD patient were gathered from the general population. The median follow-up period was 5.9 years (range 0–20.8). We used the hospital discharge register to gather all hospital visits and diagnoses. Closure complications and echocardiographic changes were collected from the electronic health records.Results Transcatheter ASD closure was performed in 1000 patients (68.5% females) during the study period. The median (range) age at the time of the procedure was 37.9 (1.8–87.5) years. ASD patients had an increased risk for new-onset atrial fibrillation (RR 2.45, 95% CI: 1.84–3.25), migraine (RR 3.61, 95% CI: 2.54–5.14), ischemic heart disease (RR 1.73, 95% CI: 1.23–2.45), ventricular fibrillation/tachycardia (RR 3.54 (95% CI: 1.48–8.43) and AV conduction disorder (RR 3.60, 95% CI: 1.94–6.70) compared to the control cohort. Stroke risk was not increased (RR 1.36, 95% CI: 0.91–2.03). Adverse events occurred in 6.3% (n = 63) of the patients, including four erosions and ten device embolizations.Conclusion After TC closure of ASD, patients had a higher risk of new-onset atrial fibrillation and migraine than controls without ASD. As novel findings, we found an increased risk for ischemic heart disease, AV conduction disorders, and ventricular fibrillation/tachycardia.Key messagesEven though patients have an excellent overall prognosis after percutaneous ASD closure, the increased incidence of major comorbidities like atrial fibrillation and heart failure prompts more thorough lifelong follow-up.This study’s novel findings revealed the increased risk for ischemic heart disease, AV conduction disorders, or ventricular tachycardia/fibrillation during the follow-up.Major complications after the closure are rare; erosion is seen in 0.4% of the patients and embolization in 1.0% of the patients.https://www.tandfonline.com/doi/10.1080/07853890.2023.2178669Atrial septal defectcongenital heart diseaseatrial fibrillationstrokemigrainecomplication
spellingShingle V. Muroke
M. Jalanko
J. Haukka
J. Hartikainen
A. Tahvanainen
H. Ukkonen
K. Ylitalo
J. Pihkala
J. Sinisalo
Outcome of transcatheter atrial septal defect closure in a nationwide cohort
Annals of Medicine
Atrial septal defect
congenital heart disease
atrial fibrillation
stroke
migraine
complication
title Outcome of transcatheter atrial septal defect closure in a nationwide cohort
title_full Outcome of transcatheter atrial septal defect closure in a nationwide cohort
title_fullStr Outcome of transcatheter atrial septal defect closure in a nationwide cohort
title_full_unstemmed Outcome of transcatheter atrial septal defect closure in a nationwide cohort
title_short Outcome of transcatheter atrial septal defect closure in a nationwide cohort
title_sort outcome of transcatheter atrial septal defect closure in a nationwide cohort
topic Atrial septal defect
congenital heart disease
atrial fibrillation
stroke
migraine
complication
url https://www.tandfonline.com/doi/10.1080/07853890.2023.2178669
work_keys_str_mv AT vmuroke outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort
AT mjalanko outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort
AT jhaukka outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort
AT jhartikainen outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort
AT atahvanainen outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort
AT hukkonen outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort
AT kylitalo outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort
AT jpihkala outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort
AT jsinisalo outcomeoftranscatheteratrialseptaldefectclosureinanationwidecohort